In brief: ResMed, Meditech, Ventracor
Friday, 04 February, 2005
ResMed (ASX:RMD) shares were up almost 5 per cent today after the company announced record revenue and income results for the quarter ended December 31. Revenue for the quarter was US$103.9 million, a 26 per cent increase over the same quarter last year. Net income for the quarter was US$17.4 million.
Bob Moses has announced that he will not seek re-election as chairman of Meditech (ASX:MTR) at the company's annual general meeting, to be held in March. Meditech intends to appoint a new director by the end of the first quarter.
Ventracor (ASX:VCR) has received permission to begin recruiting patients for the CE Mark trial of its VentrAssist heart pump in Norway through the Rikshopitalet University Hospital in Oslo, one of the largest heart transplant centres in Europe.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
